证券代码：688613 证券简称：奥精医疗 公告编号：023-049 具体内容详见同日披露于上海证券交易所网站（www.sse.com.cn）的《奥精 医疗科技股份有限公司 2023 年半年度报告》及其摘要。 奥精医疗科技股份有限公司 第二届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 奥精医疗科技股份有限公司（以下简称"公司"）第二届监事会第五次会议 于 2023 年 8 月 22 日在北京市大兴区永旺西路 26 号院 2 号楼 4 层会议室以现场 结合通讯表决的方式召开。会议通知已通过邮件的方式送达各位监事。本次会议 应出席监事 3 人，实际出席监事 3 人，会议由监事会主席吴永强主持。会议的召 集和召开程序符合有关法律、法规、规章和《奥精医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的规定。 二、监事会会议审议情况 经与会监事认真审议，做出如下决议： （一）审议通过《<2023 年半年度报告>及其摘要的议案》 经审议，公司监事会全体监事认为公司《2023 年半 ...

证券代码：688613 证券简称：奥精医疗 公告编号：2023-044 奥精医疗科技股份有限公司持股 5%以上股东 | 股东名称 | | 股东身份 | 持股数量（股） | 持股比例 | | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | --- | | 嘉兴华控 | 5% | 以上第一大 | 6,853,111 | 5.1398% | IPO | 前取得：6,853,111 | | | 股东 | | | | 股 | | 大股东持股的基本情况 本次减持计划实施前，奥精医疗科技股份有限公司（以下简称 "公司" 或 "奥精医疗"）股东嘉兴华控创业投资合伙企业（有限合伙）（曾用名：嘉兴华控 股权投资基金合伙企业(有限合伙)，以下简称"嘉兴华控"）持有公司 6,853,111 股股份，占奥精医疗总股份的 5.1398%，上述股份为嘉兴华控于公司首次公开发 行并上市前取得的股份，且于 2022 年 5 月 23 日起上市流通。 减持计划的实施结果情况 2023 年 3 月 21 日，公司披露了《奥精医疗科技股份有限公司股东减持股份 计划公告》（公告编号：2023-009） ...

证券代码：688613 证券简称：奥精医疗 公告编号：2023-037 奥精医疗科技股份有限公司 关于参加2022年度医疗设备专场集体业绩说明会的公告 投资者可于 2023年6月14日 (星期三)16:00 前通过邮件、电话、传真等形式 将需要了解和关注的问题提前提供给公司。公司将在说明会上对投资者普遍关注的 问题进行回答。 奥精医疗科技股份有限公司 (以下简称"公司")已于 2023年4月21日发布公司 2022年年度报告，为便于广大投资者更全面深入地了解公司2022年度经营成果、财 务状况、发展理念，公司参与了由上交所主办的 2022 年度医疗设备专场集体业绩 说明会，此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券 交易所上证路演中心 (http://roadshow.sseinfo.com/) 参与线上互动交流。 本次投资者说明会以视频和网络互动形式召开，公司将针对 2022 年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通， 在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其 ...

Financial Performance - In 2022, the company's operating revenue was CNY 245.31 million, representing a year-on-year increase of 3.92%[21]. - The net profit attributable to shareholders was CNY 95.22 million, a decrease of 21.17% compared to the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 80.06 million, down 17.86% year-on-year[24]. - The net cash flow from operating activities decreased by 21.35% to CNY 102.05 million[24]. - Total assets increased by 2.32% year-on-year, reaching CNY 1.46 billion[24]. - The basic earnings per share decreased by 29.7% to CNY 0.71[22]. - The weighted average return on net assets dropped to 7.37%, a decrease of 9.82 percentage points compared to the previous year[23]. - The company reported quarterly revenues of CNY 45.89 million, CNY 58.45 million, CNY 71.63 million, and CNY 69.34 million for Q1 to Q4 respectively[26]. Research and Development - The R&D expenditure as a percentage of operating revenue rose to 23.42%, an increase of 9.34 percentage points from the previous year[23]. - In 2022, the company invested CNY 57.46 million in R&D, accounting for 23.42% of its revenue[35]. - The company achieved significant progress in its product pipeline, with two projects entering clinical trial stages, including collagen protein sponge and mineralized collagen/polyester artificial bone repair materials[35]. - The company was granted 9 invention patents by the National Intellectual Property Administration of China, bringing the total to 54 patents by the end of the reporting period[36]. - The company published 3 academic papers and released an academic monograph titled "Biomimetic Materials for Biomedical Applications" in October 2022[36]. - The company’s core technologies include biomimetic mineralization technology and collagen extraction and purification technology, all of which are proprietary innovations[60]. - The company is involved in a national key R&D project focused on new generation biomimetic mineralized collagen implants, which is progressing as planned[62]. Market Expansion and Sales - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]. - In 2022, the company added over 150 distributors and developed more than 200 new hospitals, resulting in a positive sales trend and stable growth in its main business[37]. - The company primarily generates revenue through the sale of mineralized collagen artificial bone repair materials to distributors and hospitals[42]. - The company has expanded its product line to cover all provinces, cities, and autonomous regions in China, with over 200 new terminal hospitals added during the reporting period, receiving unanimous recognition from clinical experts[51]. - The company is focusing on optimizing the characteristics of scaffold materials and advancing the theoretical framework and product design of bone tissue engineering for future development of artificial bone repair materials[47]. Governance and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[4]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties[7]. - There are no violations of decision-making procedures regarding external guarantees[7]. - The company has established a comprehensive internal control system to ensure effective business operations and compliance with regulatory requirements[39]. - The company has received a standard unqualified audit report from its accounting firm[5]. - The company completed the election of its second board of directors and supervisory board on November 29, 2022[34]. Employee and Management - The company has a structured employee compensation system based on job responsibilities, performance, and market competitiveness[173]. - The employee compensation structure includes basic salary, position salary, performance salary, and bonuses, ensuring a comprehensive approach to employee remuneration[173]. - The total number of R&D personnel remained at 19, with an increase in average salary from 42.50 million RMB to 58.93 million RMB, reflecting a growth of 38.6%[70]. - The company has a strong R&D team with members recognized as top talents in Beijing, contributing to its innovative capabilities and successful project execution[73]. - The company has implemented an annual training plan that includes various training programs for new and existing employees, utilizing both internal and external resources[174]. Social Responsibility and Environmental Impact - The company invested 1.90 million yuan in environmental protection during the reporting period[189]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[190]. - The company has implemented measures to optimize processes and improve resource utilization to reduce carbon emissions[195]. - The company actively engages in social responsibility, contributing to sustainable economic, social, and environmental development[197]. - The company made a donation of 0.5 million yuan to a school as part of its charitable activities[198]. Future Outlook - The company provided guidance for 2023, expecting revenue to reach between 1.7 billion and 1.8 billion, indicating a growth rate of approximately 13% to 20%[152]. - The company plans to enhance its digital marketing strategy, aiming for a 50% increase in online sales channels[152]. - The company is focusing on expanding new products and markets to effectively increase revenue and profit scales[134]. - The company aims to enhance its core business and expand market presence in 2023, focusing on product development to drive sustained revenue growth[135].

2023 年第一季度报告 证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 (二)非经常性损益项目和金额 单位：元 币种：人民币 | 项目 | 本期金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益 | | | | 越权审批，或无正式批准文件， | | | | 或偶发性的税收返还、减免 | | | | 计入当期损益的政府补助，但与 | 119,171.30 | | | 公司正常经营业务密切相关，符 | | | | 合国家政策规定、按照一定标准 ...

2022 年第三季度报告 证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 期末比上年 | | | | 减变动幅度 | | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 71,629,888.93 | 12.77 | 175,969,143.1 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2022, with total revenue reaching RMB 100 million, representing a growth of 25% year-over-year[15]. - The company's revenue for the first half of 2022 was approximately ¥104.34 million, representing a year-on-year increase of 14.36%[22]. - The company reported a revenue increase of 15% year-over-year for the first half of 2022, reaching $500 million[98]. - The company achieved total operating revenue of 104.34 million yuan, representing a year-on-year growth of 14.36%[55]. - The company reported a total revenue of RMB 104,961,913.05, representing a 41.00% increase compared to the previous period[150]. Profitability - Net profit attributable to shareholders for the same period was approximately ¥32.83 million, a decrease of 30.57% compared to the previous year[22]. - Basic earnings per share decreased by 44.44% to ¥0.25 from ¥0.45 in the same period last year[21]. - The net profit attributable to shareholders decreased by 30.57% to 32.83 million yuan, while the net profit excluding non-recurring gains and losses dropped by 23.87% to 28.08 million yuan[55]. - The company’s net profit for the first half of 2022 was CNY 40,817,639.73, a decrease of 28.2% compared to CNY 56,800,982.33 in the same period of 2021[192]. - Operating profit for the first half of 2022 was CNY 43,028,209.28, down 34.9% from CNY 66,136,741.82 in the first half of 2021[192]. Research and Development - The company has invested RMB 5 million in R&D for new technologies aimed at improving product efficacy and safety[15]. - Research and development expenses accounted for 28.76% of operating revenue, an increase of 16.39 percentage points year-on-year[21]. - R&D expenditures reached approximately ¥30 million, a significant increase of 166.16% from ¥11.27 million in the previous year[41]. - The company established a joint research center with Tsinghua University for the development of high-performance biomedical materials, incurring a payment of ¥10 million in the first quarter of 2022[23]. - The company is actively pursuing patent registrations for its innovations, with several patents expected to be authorized by 2024[46]. Market Expansion - User data indicates that the company has expanded its customer base by 15%, now serving over 50,000 active users[15]. - The company has provided a positive outlook for the second half of 2022, projecting a revenue growth of 30% compared to the first half[15]. - The company is actively pursuing market expansion strategies, targeting three new provinces for distribution by Q4 2022[15]. - The company is focused on expanding its market presence in the high-end biomedical materials sector, aiming to provide safe and high-quality products and services[28]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2023[98]. Strategic Initiatives - A strategic acquisition of a smaller competitor is in progress, which is anticipated to enhance market share by 10%[15]. - The company aims to enhance its market competitiveness by developing high-end biomedical materials and expanding into overseas markets[32]. - The management has outlined a plan to increase production capacity by 20% to meet rising demand[15]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $100 million allocated for potential deals[98]. - The company aims to enhance customer engagement through a new loyalty program, expected to increase customer retention by 15%[98]. Financial Stability - The company has maintained a strong balance sheet with a cash reserve of RMB 50 million, ensuring financial stability for future investments[15]. - The company’s total assets increased by 6.06% to approximately ¥1.46 billion compared to the end of the previous year[22]. - The company’s cash and cash equivalents increased by 10% to ¥719,278,273.46, representing 49.21% of total assets[80]. - The company’s long-term borrowings decreased by 9.38% to ¥51,200,000.00, primarily due to repayments[80]. - The company’s financing activities resulted in a net cash outflow of ¥5,302,572.11, a decrease of 101.02% compared to the previous year due to last year's fundraising from the IPO[77]. Risks and Challenges - No significant risks were identified during the reporting period that could adversely affect the company's operations[4]. - The company faces risks related to market competition, as the medical device industry has seen rapid growth and increased competition from both domestic and international players[63]. - There is a risk of declining market demand for the company's products if there are changes in disease patterns or treatment methods, which could negatively impact sales[64]. - The company is exposed to risks associated with the concentration of key raw material suppliers, which could impact production if supply is disrupted[66]. - The company has established a research and development system focused on clinical needs and independent innovation, but faces risks related to new product development and potential technical failures[71]. Environmental and Social Responsibility - The company reported no significant environmental pollution issues during its operations, with wastewater primarily from production processes and daily office activities[90]. - The company has implemented measures to treat wastewater, including centralized collection and treatment at municipal facilities[92]. - Noise generated from production is managed through effective layout and sound insulation measures[92]. - Solid waste management includes recycling of industrial solid waste and proper disposal of hazardous and medical waste by qualified units[92]. - The company has committed to fulfilling various promises related to share restrictions and has complied with these commitments[95].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 45,892,651.03, representing a year-on-year increase of 25.10%[4] - The net profit attributable to shareholders decreased by 27.32% to CNY 13,148,745.08 compared to the same period last year[4] - Total operating revenue for Q1 2022 was CNY 45,892,651.03, an increase of 25.5% compared to CNY 36,686,118.23 in Q1 2021[20] - Net profit for Q1 2022 was CNY 11,205,537.61, a decrease of 35.2% from CNY 17,318,208.78 in Q1 2021[21] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.10, down from CNY 0.18 in Q1 2021[22] Research and Development - R&D expenses totaled CNY 18,387,296.71, accounting for 40.07% of operating revenue, an increase of 12.01 percentage points year-on-year[5] - R&D expenses for Q1 2022 were CNY 18,387,296.71, significantly higher than CNY 4,407,131.12 in Q1 2021, reflecting a focus on innovation[21] - The company established a joint research center with Tsinghua University for high-performance biomedical materials, resulting in increased R&D expenses[5] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 8,833,565.49, down 67.13% from the previous year[5] - The company reported a decrease in cash flow from operating activities, reflecting challenges in cash generation[23] - Cash received from sales and services in Q1 2022 was approximately ¥58.46 million, up from ¥39.78 million in Q1 2021, representing a growth of 46.9%[25] - Net cash flow from operating activities in Q1 2022 was ¥8.83 million, a decrease of 67.2% compared to ¥26.88 million in Q1 2021[25] - Cash and cash equivalents at the end of Q1 2022 totaled ¥363.57 million, down from ¥411.31 million at the beginning of the quarter, indicating a decrease of 11.6%[26] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,431,884,176.89, a slight increase of 0.41% from the end of the previous year[5] - The total liabilities for Q1 2022 were CNY 150,096,282.51, down from CNY 155,494,830.72 in Q1 2021[18] - The company holds non-current assets totaling RMB 305,380,078.84, which is a slight increase from RMB 305,190,726.17[16] - Total liabilities stood at ¥155.49 million, with current liabilities accounting for ¥55.18 million[29] Shareholder Information - The company has a significant shareholder, Jiaxing Huakong Investment Partnership, holding 12,976,445 shares, representing 9.73% of total shares[12] - The second-largest shareholder, Beijing Qilun Tianyou Venture Capital, holds 12,090,933 shares, accounting for 9.07%[12] Future Outlook - The company plans to continue investing in R&D and market expansion to drive future growth[21] - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[26] Other Information - The company has not disclosed any new product developments or technological advancements during this reporting period[14] - There are no significant mergers or acquisitions reported in the current quarter[14] - The company has not provided specific future guidance or market expansion strategies in this report[14]

2021 年年度报告 公司代码：688613 公司简称：奥精医疗 奥精医疗科技股份有限公司 2021 年年度报告 1 / 209 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 □是 √否 三、 重大风险提示 报告期内，不存在对公司生产经营构成实质性影响的重大风险。公司已于本报告中详细描述 了存在的相关风险，详见"第三节管理层讨论与分析"中关于公司风险因素的相应内容。 四、 公司全体董事出席董事会会议。 五、 立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人 Eric Gang Hu（胡刚）、主管会计工作负责人于秀荣及会计机构负责人（会计主管 人员）王玲声明：保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第一届董事会第十三次会议审议通过，公司2021年度拟以实施权益分派股权登记日的 总股本为基数分配利润，本次利润分配预 ...

2021 年第三季度报告 证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 同期增减变 | | | | 动幅度(%) | | 动幅度(%) | | 营业收入 | 63,519,297.92 | 4.8 | 154,753,320.07 | 51.36 | | ...